These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 31017739)

  • 1. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
    Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
    Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.
    Li Y; Wang K; Zhao E; Li B; Li S; Dong X; Yuan L; Yang H
    Pathol Oncol Res; 2022; 28():1610245. PubMed ID: 35721326
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
    Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
    JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
    Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma.
    Huang J; Xu B; Mo H; Zhang W; Chen X; Wu D; Qu D; Wang X; Lan B; Yang B; Wang P; Zhang H; Yang Q; Jiao Y
    Clin Cancer Res; 2018 Mar; 24(6):1296-1304. PubMed ID: 29358502
    [No Abstract]   [Full Text] [Related]  

  • 8. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
    Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.
    Yan Z; Yao ZH; Yao SN; Wang HY; Chu JF; Song M; Zhao S; Liu YY
    Immunotherapy; 2020 Nov; 12(16):1161-1166. PubMed ID: 32814482
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
    Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
    Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial.
    He M; Wang Z; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Sheng Z; Zeng W; Song L; Xu RH; Luo H
    Med; 2024 Sep; 5(9):1137-1149.e3. PubMed ID: 38870932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
    Ning T; Li D; Deng T; Bai Y; Chen Y; Wang Z; Hu B; Ba Y; Lu W
    Cancer; 2024 Sep; 130(18):3137-3146. PubMed ID: 38781433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
    Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
    Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
    Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
    Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma.
    Wei XL; Zhang DS; He MM; Jin Y; Wang DS; Zhou YX; Bai L; Li ZZ; Luo HY; Wang FH; Xu RH
    Tumour Biol; 2016 Feb; 37(2):1879-87. PubMed ID: 26323257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study.
    Zhang W; Yan C; Zhang T; Chen X; Dong J; Zhao J; Han D; Wang J; Zhao G; Cao F; Zhou D; Jiang H; Tang P; Zhao L; Yuan Z; Wang Q; Wang P; Pang Q
    Oncoimmunology; 2021; 10(1):1971418. PubMed ID: 34616588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12).
    Lee DK; Park SR; Kim YH; Lee YG; Shin SJ; Ahn BC; Lee SS; Lim SM; Kim HR; Cho BC; Hong MH
    Oncoimmunology; 2024; 13(1):2371563. PubMed ID: 38919826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.
    Lu J; Du L; Lei X; Zhang Z
    Cancer Med; 2023 May; 12(10):11334-11343. PubMed ID: 36951584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-dimer levels predict the treatment efficacy and prognosis of esophageal squamous cell carcinoma treated with PD-1/PD-L1 inhibitors.
    Wu Y; Liu X; Li H; Wang W; Ye L; Zhou Y; Chen D
    Int J Biol Markers; 2024 Sep; 39(3):209-216. PubMed ID: 38887052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma.
    Chen Y; Zhuang L; Zhang D; Du X; Sheng L
    J Immunol Res; 2022; 2022():4015897. PubMed ID: 35832645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.